TTS Pharma develops and supplies purified cannabis-derived active agents and finished CBD products across wellness, nutraceutical and pharmaceutical segments. The company operates a vertically integrated supply chain covering cultivation, extraction, separation, purification and drug delivery, and has both domestic and international partners. It began a comprehensive R&D sponsorship programme in mid-2018 to extract and characterize cannabinoids and has begun sales of highly purified cannabis-related products and technologies. TTS Pharma aims to expand its existing supply chain, develop its own facilities, and strengthen academic and commercial partnerships to scale in the emerging ethical cannabis market. The company emphasizes regulatory compliance and intends to obtain requisite permissions for broader commercial distribution. TTS Pharma is incorporated in England and Wales (established 2012) and maintains offices in London and Liverpool. TTS Pharma develops a personalized nicotine patch paired with a companion diagnostic blood test intended to tailor nicotine dosing and improve quit rates for smokers. The company’s lead product combines a blood-test companion diagnostic with a patch technology to deliver a tailored dose of nicotine. TTS Pharma intends to use recently raised capital to secure regulatory approval for the lead product and to commercialize it in the UK, Europe and other select markets. The company is led by CEO Mark Tucker. TTS Pharma is relocating from Bristol to Liverpool Science Park early next year. The article does not disclose operating metrics such as revenue or user counts.

Total raised

$14M

Funding rounds

2

Latest round

Series B

Latest activity

May 2019